<DOC>
	<DOC>NCT02218008</DOC>
	<brief_summary>This study will evaluate the efficacy and safety of ALKS 5461.</brief_summary>
	<brief_title>A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - FORWARD-5 Study</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder, Major</mesh_term>
	<criteria>Have a BMI of 18.0 to 40.0 kg/m2, inclusive Agree to use an acceptable method of contraception for the duration of the study Have an MDD primary diagnosis Have no more than 2 inadequate responses to antidepressant therapy (ADT) in the current Major Depressive Episode (MDE) Additional criteria may apply Have a current primary AxisI disorder other than MDD Have used opioid agonists (eg, codeine, oxycodone, tramadol, morphine) or opioid antagonists (eg, naloxone, naltrexone) within 14 days Have received electroconvulsive therapy treatment within the last 2 years or received more than one course of electroconvulsive treatment during their lifetime Have attempted suicide within the past 2 years Have a positive test for drugs of abuse Are pregnant, planning to become pregnant, or breastfeeding Have a history of intolerance, allergy, or hypersensitivity to buprenorphine or opioid antagonists (eg, naltrexone, naloxone) Have had a significant blood loss or blood donation within 60 days Additional criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Major depressive disorder (MDD)</keyword>
	<keyword>depression</keyword>
	<keyword>Alkermes</keyword>
	<keyword>ALKS 5461</keyword>
	<keyword>samidorphan</keyword>
</DOC>